Risk profiling of patients with relapsed/refractory diffuse large B-cell lymphoma by measuring circulating tumor DNA
Alex F Herrera, Samuel Tracy, Brandon Croft, Stephen Opat, Jill Ray, Alex F Lovejoy, Lisa Musick, Joseph N Paulson, Laurie H Sehn, Yanwen Jiang, Alex F Herrera, Samuel Tracy, Brandon Croft, Stephen Opat, Jill Ray, Alex F Lovejoy, Lisa Musick, Joseph N Paulson, Laurie H Sehn, Yanwen Jiang
Abstract
Patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) have heterogeneous outcomes; durable remissions are infrequently observed with standard approaches. Circulating tumor DNA (ctDNA) assessment is a sensitive, potentially prognostic tool in this setting. We assessed baseline ctDNA to identify patients with R/R DLBCL at high risk of relapse after receiving polatuzumab vedotin and bendamustine plus rituximab (BR) or BR alone. Patients were transplant ineligible and had received ≥1 prior line of therapy. The ctDNA assay, based on a customized panel of recurrently mutated genes in DLBCL, measured mutant molecules per mL (MMPM) at baseline and end of treatment (EOT). Endpoints included progression-free survival (PFS) and overall survival (OS) in subgroups stratified by baseline ctDNA and log-fold change in ctDNA at EOT vs baseline. In biomarker-evaluable patients (n = 33), baseline ctDNA level correlated with serum lactate dehydrogenase (LDH) concentration, number of prior therapies, stage, and International Prognostic Index (IPI). After adjusting for number of prior therapies ≥2, IPI score ≥3, and LDH above the upper limit of normal, high (greater than median) baseline ctDNA MMPM was independently prognostic for shorter PFS (adjusted hazard ratio [HR], 0.18 [95% CI, 0.05-0.65]) and OS (adjusted HR, 0.20 [95% CI, 0.06-0.68]). In 23 patients with baseline and EOT samples, a significantly greater decrease in ctDNA MMPM was observed in patients with complete response (CR) (n = 13) than those without CR (n = 10); P = .0025. Baseline ctDNA assessment may identify patients at high risk of progression and should be further evaluated as a monitoring tool in R/R DLBCL. This trial was registered at www.clinicaltrials.gov as #NCT02257567.
© 2022 by The American Society of Hematology. Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0), permitting only noncommercial, nonderivative use with attribution. All other rights reserved.
Figures
References
- Sehn LH, Salles G. Diffuse large B-cell lymphoma. N Engl J Med. 2021;384(9):842-858.
- Polson AG, Calemine-Fenaux J, Chan P, et al. . Antibody-drug conjugates for the treatment of non-Hodgkin’s lymphoma: target and linker-drug selection [published correction appears in Cancer Res. 2010;70(3):1275]. Cancer Res. 2009;69(6):2358-2364.
- Okazaki M, Luo Y, Han T, Yoshida M, Seon BK. Three new monoclonal antibodies that define a unique antigen associated with prolymphocytic leukemia/non-Hodgkin’s lymphoma and are effectively internalized after binding to the cell surface antigen. Blood. 1993;81(1):84-94.
- U.S. Food and Drug Administration. POLIVY U.S. Prescribing Information. . Accessed 5 March 2021.
- EMA. POLIVY: product information. . Accessed 5 March 2021.
- Sehn LH, Herrera AF, Flowers CR, et al. . Polatuzumab vedotin in relapsed or refractory diffuse large B-cell lymphoma. J Clin Oncol. 2020;38(2):155-165.
- Kurtz DM, Scherer F, Jin MC, et al. . Circulating tumor DNA measurements as early outcome predictors in diffuse large B-Cell lymphoma. J Clin Oncol. 2018;36(28):2845-2853.
- Roschewski M, Dunleavy K, Pittaluga S, et al. . Circulating tumour DNA and CT monitoring in patients with untreated diffuse large B-cell lymphoma: a correlative biomarker study. Lancet Oncol. 2015;16(5):541-549.
- Alig S, Macaulay CW, Kurtz DM, et al. . Short diagnosis-to-treatment interval is associated with higher circulating tumor DNA levels in diffuse large B-cell lymphoma. J Clin Oncol. 2021;39(23):2605-2616.
- Frank MJ, Hossain NM, Bukhari AA, et al. . Monitoring ctDNA in r/r DLBCL patients following the CAR T-cell therapy axicabtagene ciloleucel: day 28 landmark analysis. J Clin Oncol. 2019;37(15 _suppl):7552-7552.
- Newman AM, Lovejoy AF, Klass DM, et al. . Integrated digital error suppression for improved detection of circulating tumor DNA. Nat Biotechnol. 2016;34(5):547-555.
- Scherer F, Kurtz DM, Newman AM, et al. . Distinct biological subtypes and patterns of genome evolution in lymphoma revealed by circulating tumor DNA. Sci Transl Med. 2016;8(364):364ra155.
- Cingolani P, Platts A, Wang le L, et al. . A program for annotating and predicting the effects of single nucleotide polymorphisms, SnpEff: SNPs in the genome of Drosophila melanogaster strain w1118; iso-2; iso-3. Fly (Austin). 2012;6(2):80-92.
- Pati A, Lovejoy A, Shi PW, et al. . Detection of minimal residual disease from less than one cell equivalent in liquid biopsy samples using the AVENIO ctDNA Surveillance Kit. Cancer Res. 2018;78(13 suppl):4574.
- Casasnovas RO, Ysebaert L, Thieblemont C, et al. . FDG-PET-driven consolidation strategy in diffuse large B-cell lymphoma: final results of a randomized phase 2 study. Blood. 2017;130(11):1315-1326.
- Stiff PJ, Unger JM, Cook JR, et al. . Autologous transplantation as consolidation for aggressive non-Hodgkin’s lymphoma. N Engl J Med. 2013; 369(18):1681-1690.
- Swinnen LJ, Li H, Quon A, et al. . Response-adapted therapy for aggressive non-Hodgkin’s lymphomas based on early [18F] FDG-PET scanning: ECOG-ACRIN Cancer Research Group study (E3404). Br J Haematol. 2015;170(1):56-65.
- Hertzberg M, Gandhi MK, Trotman J, et al. ; Australasian Leukaemia Lymphoma Group (ALLG) . Early treatment intensification with R-ICE and 90Y-ibritumomab tiuxetan (Zevalin)-BEAM stem cell transplantation in patients with high-risk diffuse large B-cell lymphoma patients and positive interim PET after 4 cycles of R-CHOP-14. Haematologica. 2017;102(2):356-363.
- Chiappella A, Martelli M, Angelucci E, et al. . Rituximab-dose-dense chemotherapy with or without high-dose chemotherapy plus autologous stem-cell transplantation in high-risk diffuse large B-cell lymphoma (DLCL04): final results of a multicentre, open-label, randomised, controlled, phase 3 study. Lancet Oncol. 2017;18(8):1076-1088.
- Macaulay C, Alig S, Kurtz DM, et al. . Interim circulating tumor DNA as a prognostic biomarker in the setting of interim PET-based adaptive therapy for DLBCL. Am J Hematol. 2019;134(suppl 1):1600.
- Xu-Monette ZY, Wu L, Visco C, et al. . Mutational profile and prognostic significance of TP53 in diffuse large B-cell lymphoma patients treated with R-CHOP: report from an International DLBCL Rituximab-CHOP Consortium Program Study. Blood. 2012;120(19):3986-3996.
- Peroja P, Pedersen M, Mantere T, et al. . Mutation of TP53, translocation analysis and immunohistochemical expression of MYC, BCL-2 and BCL-6 in patients with DLBCL treated with R-CHOP. Sci Rep. 2018;8(1):14814.
- Young KH, Weisenburger DD, Dave BJ, et al. . Mutations in the DNA-binding codons of TP53, which are associated with decreased expression of TRAILreceptor-2, predict for poor survival in diffuse large B-cell lymphoma. Blood. 2007;110(13):4396-4405.
- Rushton CK, Arthur SE, Alcaide M, et al. . Genetic and evolutionary patterns of treatment resistance in relapsed B-cell lymphoma. Blood Adv. 2020;4(13):2886-2898.
- Pessoa LS, Heringer M, Ferrer VP. ctDNA as a cancer biomarker: a broad overview. Crit Rev Oncol Hematol. 2020;155:103109.
- Kristensen LS, Hansen JW, Kristensen SS, et al. . Aberrant methylation of cell-free circulating DNA in plasma predicts poor outcome in diffuse large B cell lymphoma. Clin Epigenetics. 2016;8(1):95.
- Wedge E, Hansen JW, Garde C, et al. . Global hypomethylation is an independent prognostic factor in diffuse large B cell lymphoma. Am J Hematol. 2017;92(7):689-694.
Source: PubMed